Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Greenleaf Offers Full Portfolio of Digital Health Services

Greenleaf Health, Inc. (Greenleaf), a leading Food and Drug Administration (FDA) regulatory consulting firm, announces the firm’s complete portfolio of services to support companies developing, commercializing, utilizing, and investing in innovative digital health technologies.

Latest Aithority Insights: Auterion Delivers Supercomputer Performance Onboard Drones and Mobile Robots With AI Node

“Players in the digital health space face unique challenges in navigating an ever-changing regulatory landscape, as FDA regulators try to keep up with the pace of digital health technology development”

“Players in the digital health space face unique challenges in navigating an ever-changing regulatory landscape, as FDA regulators try to keep up with the pace of digital health technology development,” said John Taylor, President, Greenleaf Health, and Principal, Compliance and Regulatory Affairs. “Greenleaf serves as a trusted partner to both large and small clients developing and commercializing innovative digital health technologies as they navigate the complex landscape of FDA regulations and policies.”

Browse The Complete News About Aithority : TaskHuman Adds 1:1 Sales Coaching to Accelerate Time to Revenue for Global Sales Teams

Related Posts
1 of 27,439

STRATEGIC & TECHNICAL GUIDANCE
Greenleaf professionals work as teams specializing in medical devices and combination products; product quality, manufacturing, and compliance; and drug and biological products. Greenleaf’s comprehensive approach provides a full-service engagement that ensures clients can count on expert direction as they encounter complex regulatory challenges. Greenleaf offers the following digital health-focused services:

Regulatory Strategy & Compliance
Greenleaf experts provide insight, clarity, and strategic consultation on digital health topics. Regulatory strategy and compliance services include:
– Advise clients on FDA regulatory policies, programs, and procedures, including questions related to jurisdiction to regulate, device classification, and potential pathways to market
– Partner with clients to design strategies for product development and premarket review
– Assist with marketing application preparation and submission
– Provide advice regarding FDA communications, including compliance and regulatory correspondence
– Advise on FDA labeling and postmarket safety requirements

Advisory Services
Greenleaf professionals assist entities involved in digital health technology investments and transactions. Advisory services include:
– Perform due diligence and regulatory risk assessments of potential targets
– Advise investors on opportunities to manage and mitigate risks in order to achieve desired regulatory outcomes
– Research and analyze regulatory data sources

Regulatory Policy
Greenleaf’s cross-functional teams help clients keep pace with developments and navigate the emerging regulatory landscape. Regulatory policy services include:
– Identify novel regulatory tools and approaches to optimize the development process
– Support clients in structuring their regulatory policy capabilities to effectively advance priorities
– Design and implement strategies that engage stakeholders, leverage alliances, and advance regulatory policy

Read More About Aithority News : Milesight Blossoms into Mighty AIoT Solution Provider with Leading-Edge Products and Solutions

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.